Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 14, 2019

FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

Amgen and Allergan have secured approval from the US Food and Drug Administration (FDA) for Kanjinti (trastuzumab-anns), a biosimilar to Roche’s Herceptin (trastuzumab).

Image: Amgen headquarters in Thousand Oaks, California. Photo: courtesy of Coolcaesar.